TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02057133
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT02057133
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT02057133
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT02057133
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT02057133
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV infusion.
Study: NCT02057133
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered IM.
Study: NCT02057133
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV infusion.
Study: NCT02057133
Drug: Loperamide
Normalized name: Loperamide
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00427102
Drug: Oral MRX-1024
Normalized name: MRx-4DP0004
DrugBank: MRx-4DP0004 (DB15751)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00427102
Drug: High-Dose Cisplatin Chemotherapy
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01059422
Drug: Raltegravir; Abacavir/Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir: 400 mg twice daily Abacavir/Lamivudine fixed-dose combination: 600mg/300mg once daily
Study: NCT03213002
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide at 150 mg/m2 - 200 mg/m2
Study: NCT00684411
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01011751
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate tablet-in-capsule.
Study: NCT01011751
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate tablet-in-capsule.
Study: NCT01011751
Drug: Venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine capsule.
Study: NCT01011751
Drug: Leuprorelin
Normalized name: Leuprorelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin injection.
Study: NCT01011751
Drug: Flutamide
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide tablet
Study: NCT04258644
Drug: Camrelizumab+Apatinib+Paclitaxel-albumin+S-1
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination therapy of 4 drugs, 21 days for one cycle.
Study: NCT00439712
Drug: Levocetirizine
Normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet of Levocetirizine 5 mg OD in the morning for 29+/-4 days
Study: NCT01513720
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine Tablets 200 mg
Study: NCT01135329
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2 IV daily on Day -6 through Day -2.
Study: NCT01135329
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg/kg PO OR 0.8 mg/kg IV four times daily on Day -6 through Day -3.
Study: NCT01135329
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg/kg PO three times daily (max daily dose of 3g) starting on Day +5.
Study: NCT01135329
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed based on drug levels; begin on Day +5 at 1 mg IV daily.
Study: NCT03942458
Drug: Vicagrel 6mg
Normalized name: Vicagrel
DrugBank: Vicagrel (DB16349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicagrel 24mg loading followed by 6mg/day for 6 days
Study: NCT03942458
Drug: Clopidogrel 75mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 300mg loading followed by 75mg/day for 6 days
Study: NCT04016389
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
Study: NCT04016389
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
Study: NCT04016389
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel is an antineoplastic agent that is commonly used in combination with cisplatin or carboplatin for the treatment of cervical cancer.
Study: NCT03656692
Drug: Acthar Gel
Normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acthar gel for subcutaneous injection 80 units per mL (40 units per 0.5 mL)
Study: NCT00444522
Drug: Alprazolam thermal aerosol
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00839800
Drug: Terbutaline Turbuhaler
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 mg
Study: NCT01598493
Drug: Flamazine
Normalized name: Flamazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine cream
Study: NCT00790010
Drug: Bevacizumab Plus Ipilimumab Cohort 1
Normalized name: Ipilimumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 1: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
Study: NCT00790010
Drug: Bevacizumab Plus Ipilimumab Cohort 2
Normalized name: Ipilimumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 2: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
Study: NCT00790010
Drug: Bevacizumab Plus Ipilimumab Cohort 3
Normalized name: Ipilimumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 3: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
Study: NCT00790010
Drug: Bevacizumab Plus Ipilimumab Cohort 4
Normalized name: Ipilimumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 4: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
Study: NCT00735969
Drug: Peginterferon
Normalized name: PEGINTERFERON
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00735969
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01372618
Drug: SOM 230 / Pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SOM230/Pasireotide is a multi-receptor targeted somatostatin analogue. In this trial, 600 mcg of SOM230/Pasireotide are taken twice daily subcutaneously.
Study: NCT03448419
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Film-coated tablet
Study: NCT02639624
Drug: Low bicarbonate dialysate First
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02639624
Drug: Normal bicarbonate dialysate First
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02639624
Drug: Normal bicarbonate dialysate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02639624
Drug: Low bicarbonate dialysate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03809780
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: -high dose: \[lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly\] -Low dose: \[lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly\]
Study: NCT03809780
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -high dose: \[lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly\] -Low dose: \[lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly\]
Study: NCT03058562
Drug: ABX-1431
Normalized name: ABX-1431
DrugBank: ABX-1431 (DB16036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX-1431, capsules, 40 mg in the fasting state
Study: NCT03058562
Drug: ABX-1431
Normalized name: ABX-1431
DrugBank: ABX-1431 (DB16036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX-1431, capsules, 20 mg with a high fat meal
Study: NCT02185326
Drug: Growth hormone (Norditropin, Novo nordisk)
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
Study: NCT02982681
Drug: Platelet rich fibrin
Normalized name: platelet glycoprotein VI
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site
Study: NCT02604992
Drug: Treatment C
Normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol oral capsule, under fasted conditions
Study: NCT00406341
Drug: Difluprednate Ophthalmic Emulsion
Normalized name: Difluprednate Ophthalmic Emulsion
DrugBank: Difluprednate (DB06781)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00730535
Drug: Tolterodine
Normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended release tolterodine tartrate 4 mg, once daily, for 1 months
Study: NCT00730535
Drug: Tolterodine
Normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended release tolterodine tartrate 4 mg, once daily, for 3 months
Study: NCT00703690
Drug: Comparator: fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fenofibrate 200 mg supplied as capsules
Study: NCT00730535
Drug: Tolterodine 6
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended release tolterodine tartrate 4 mg, once daily, for 6 months
Study: NCT01588158
Drug: Vicodin
Normalized name: Vicodin
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicodin 5/325 mg
Study: NCT02403479
Drug: Silver Colloid
Normalized name: SILVER COLLOIDAL
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical silver colloid will be administered for 6 weeks. This will either occur before topical saline nasal spray. Participants are randomized as to the order of sprays. The commercially available silver colloid product, Sovereign Silver Mineral Supplement, will be used.
Study: NCT02203461
Drug: Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: STRIBILD® QD, d1-14
Study: NCT02203461
Drug: Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Truvada®/ Kaletra® 200/50 mg QD, d1-14
Study: NCT02203461
Drug: Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Truvada®/Prezista® 800 mg/Norvir®100 mg Medication, QD, d1-14
Study: NCT02523183
Drug: Medical Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric patients with medically refractory epilepsy and treated with medicinal cannabis.
Study: NCT04740398
Drug: CBP-1008
Normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBP-1008 for injection; IV infusion; Infusion for 90 minutes
Study: NCT00343044
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.
Study: NCT00343044
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.
Study: NCT03268226
Drug: Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: An inhaled dose of CHF 5993 pMDI 100+6+12.5 μg twice a day (Total daily dose: BDP 400 μg / FF 24 μg / GB 50 μg)
Study: NCT00224068
Drug: Sodium ferric gluconate, ferrous sulfate, standard of care
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01314339
Drug: Desloratadine
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine Tablets, 5 mg
Study: NCT00274612
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00274612
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03824717
Drug: Dose of ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biased coin design up and down dose finding study of 0.5% ropivacaine to achieve a successful infraclavicular brachial plexus block
Study: NCT03316651
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months.
Study: NCT04349228
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 200mg/day
Study: NCT02254551
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In both the lead-in and dose expansion portions of the study, bortezomib, 1.3 mg/m2, will be administered by subcutaneous injection (SQ) on Days 1, 4, 8, 11 of each 21 day cycle.
Study: NCT03079557
Drug: Intragastric botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 200 units Botulinum toxin A (Allergan) injected intragastrically in the antrum every six months
Study: NCT03422640
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Open label treatment with apremilast
Study: NCT01175590
Drug: Besivance
Normalized name: Besivance
DrugBank: Besifloxacin (DB06771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ocular administration to affected eye for 7 days
Study: NCT02187198
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03601598
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1210 was administered 200mg iv every 2 weeks
Study: NCT03601598
Drug: SHR6390
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR6390 was administered 150mg or 100mg oral daily with 3 weeks on and 1 week off
Study: NCT02645474
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amidic local anesthetic standardly used for nerve block and infiltration
Study: NCT00740792
Drug: azelastine HCl/fluticasone propionate
Normalized name: azelastine HCl/fluticasone propionate 137 mcg-50 mcg/spray NASAL AEROSOL, SPRAY WITH PUMP (GRAM)
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: azelastine HCl 548 mcg/ fluticasone propionate 200 mcg one spray per nostril BID
Study: NCT00740792
Drug: azelastine Hcl
Normalized name: azelastine HCl
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: azelastine Hcl 548 mcg one spray per nostril BID
Study: NCT00740792
Drug: fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: fluticasone propionate 200 mcg one spray per nostril BID
Study: NCT03293992
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once daily morning or evening dosing
Study: NCT00561392
Drug: Rivastigmine 5 and 10 cm^2 patch
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04124601
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion
Study: NCT04124601
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion
Study: NCT00703586
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ARM A:~Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:~* 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~* 600 mg orally BID when coadministered with efavirenz or nevirapine~ARM B:~Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~* Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.~* Addition of an alternate FDA approved NRTI \[such as zidovudine (AZT) or didanosine (ddi)\] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.~* Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc.
Study: NCT01906216
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
Study: NCT03325816
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is administered intravenously
Study: NCT01532518
Drug: Nepadutant
Normalized name: Nepadutant
DrugBank: Nepadutant (DB12538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nepadutant oral solution
Study: NCT01050582
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: As per local prescribing practices
Study: NCT01050582
Drug: Other atypical antipsychotic drugs
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per local prescribing practices
Study: NCT00452387
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Mitoxantrone 9mg/m2~Dose Level -1 Mitoxantrone 12mg/m2~Dose Level 1 Mitoxantrone 12mg/m2
Study: NCT00795002
Drug: alvocidib
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00795002
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00795002
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00613366
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
Study: NCT01601704
Drug: NB32
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.
Study: NCT01601704
Drug: PBO
Normalized name: Zepbound
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo. Administered in addition to the weight management program.
Study: NCT01605240
Drug: Acetaminophen and Ibuprofen
Normalized name: Acetaminophen and ibuprofen only product
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and ibuprofen (10mg/kg) at regular dosing intervals.
Study: NCT01605240
Drug: Acetaminophen and Codeine
Normalized name: Acetaminophen and codeine only product
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.